Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? by Giandomenico Roviello, Silvia Paola Corona, Gabriella Nesi, Enrico Mini

Get full text

Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients by Raheleh Roudi, Mahboubeh Barodabi, Zahra Madjd, Giandomenico Roviello, Silvia Paola Corona, Mahshid Panahi

Get full text

Dual drug targeting to kill colon cancers by Silvia Paola Corona, Francesca Walker, Janet Weinstock, Guillaume Lessene, Maree Faux, Antony W. Burgess

Get full text

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer by Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

Get full text

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature by Ottavia Bernocchi, Marianna Sirico, Silvia Paola Corona, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Giuseppina Ferrero, Nicoletta Ziglioli, Valeria Cervoni, Andrea Macchiavelli, Giandomenico Roviello, Daniele Generali

Get full text

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial by Francesco Schettini, Francesco Schettini, Silvia Paola Corona, Silvia Paola Corona, Fabiola Giudici, Fabiola Giudici, Carla Strina, Marianna Sirico, Ottavia Bernocchi, Ottavia Bernocchi, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Carlo Azzini, Giuseppina Barbieri, Valeria Cervoni, Maria Rosa Cappelletti, Alfredo Molteni, Maria Chiara Lazzari, Giuseppina Ferrero, Marco Ungari, Elena Marasco, Alice Bruson, Luciano Xumerle, Elisa Zago, Davide Cerra, Marco Loddo, Gareth H. Williams, Ida Paris, Ida Paris, Giovanni Scambia, Giovanni Scambia, Daniele Generali, Daniele Generali

Get full text